GlassScriptPhysician profile
Christopher P Frazier
NPI 1366423105
$6,460.31
in general payments reported to CMS, 2019-2025
37 companies · $967 in 2025
The $967 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,277 · 2020: $175 · 2021: $393 · 2022: $940 · 2023: $1,276 · 2024: $1,433 · 2025: $967.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,676.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,675.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $984.73 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $699.34 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $589.70 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $434.19 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $410.45 | 2019-2025 | Jardiance, Stiolto Respimat, Spiriva Respimat |
| Glaxosmithkline, LLC. | $355.62 | 2019-2025 | Shingrix, Arexvy, Bexsero |
| Pfizer INC. | $325.66 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $243.78 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $234.42 | 2019-2023 | M-M-R II, Gardasil 9, Varivax |
| Sumitomo Pharma America, INC. | $174.80 | 2023-2025 | Gemtesa |
| Exact Sciences Corporation | $163.81 | 2023-2025 | Cologuard Collection Kit |
| Astellas Pharma US INC | $163.51 | 2019-2025 | Veozah, Myrbetriq |
| Abbott Laboratories | $143.42 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Takeda Pharmaceuticals U.S.A., INC. | $139.73 | 2019-2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $132.52 | 2019-2025 | Xifaxan |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Frazier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.